APVO 8-K: SEC filing
Aptevo Therapeutics
Filed with the SEC on · accession 0001193125-26-448714
APVO filed a 8-K (current report) with the SEC on Nov 5, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Aptevo Therapeutics announced a clinical development milestone for mipletamig, reporting a substantial reduction in infusion-related reactions following refinements to its priming-dose regimen.
Key details
✦ Ask GOAX AI about this filing — what it means for APVO, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for APVO?
Click hereFrequently asked questions
What did APVO file with the SEC on Nov 5, 2026?
APVO filed a 8-K (SEC filing). Aptevo Therapeutics announced a clinical development milestone for mipletamig, reporting a substantial reduction in infusion-related reactions following refinements to its priming-dose regimen.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other APVO SEC filings
Get alerts when APVO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days